| Literature DB >> 16505324 |
E R Siemers1, J F Quinn, J Kaye, M R Farlow, A Porsteinsson, P Tariot, P Zoulnouni, J E Galvin, D M Holtzman, D S Knopman, J Satterwhite, C Gonzales, R A Dean, P C May.
Abstract
LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16505324 DOI： 10.1212/01.WNL.0000198762.41312.E1
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910